{
  "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
  "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 60,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a diagram to map specific protein domains to their functional benefits.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/9",
  "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
  "deckJsonHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9.json",
  "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.11,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "NXC-201 EXPAND Technology + COBRA Binder structure",
      "attrs": null,
      "subkind": "value-chain",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c167b2c-539b-47f5-b2e6-38fafda85f70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.95,
        "x": 0.02,
        "y": 0.6
      },
      "kind": "list",
      "text": "1. Proprietary Optimized CD3zeta; 2. Proprietary Optimized CD8 Hinge Flexibility; 3. Proprietary Optimized COBRA Binder Enhances Tumor Binding + Ensures High Expression",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa259865-12e7-468c-9f70-02ace2cd6bba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.02,
        "y": 0.98
      },
      "kind": "source-note",
      "text": "Source: Aherie, N., et al Haematologica. 2022; LaFleur, D. PEGS Boston. 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06a97fc6-1e1f-4f68-818c-340e92aa1822",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "N-GENIUS Platform: EXPAND Technology + COBRA Binder (2/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f44d41b9-d4c8-4eea-bf36-bf93e3648c57",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "value-chain",
      "slug": null,
      "matchId": "279b1ae8-fbab-4cf9-bc87-beab20f56e66",
      "evidence": "The diagram maps the structural components of the NXC-201 molecule to their functional outcomes.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a",
      "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity",
      "position": 0,
      "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 60,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
      "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
      "position": 1,
      "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}